ORI Capital

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies for cancer patients. It specializes in oncolytic immunotherapy, focusing on bladder cancer treatments.

AffyImmune Therapeutics is a biopharmaceutical company focused on advancing Chimeric Antigen Receptor (CAR) T cell therapy specifically for solid tumors. The company develops genetically engineered immune cells aimed at enhancing the safety and effectiveness of cell-based immunotherapy for cancer. Utilizing a proprietary technology, AffyImmune tunes the affinity of CAR-T therapies from picomolar to micromolar levels, which is designed to reduce on-target off-tumor toxicity and broaden the applicability of these treatments to solid tumors. This innovative approach seeks to provide a more effective therapeutic option for patients suffering from various carcinogenic diseases.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies for cancer patients. It specializes in oncolytic immunotherapy, focusing on bladder cancer treatments.

Pillar Biosciences develops next-generation sequencing based assays and software for NGS laboratories. It offers SLIMamp, a Stem-Loop Inhibition-Mediated amplification technology that enables specific priming of overlapping target segments, and PiVAT, an integrated bioinformatics analysis pipeline that produces an enhanced PBAM file for improved local realignment and read assembly. Founded in 2014, the company is headquartered in Natick, Massachusetts, with a presence in Shanghai, China. Its platform focuses on targeted sequencing to support treatment decisions in oncology, delivering high sensitivity and specificity for clinical samples. Pillar has released targeted panels such as Lung and Colon Cancer Somatic Mutation Panel and BRCA1/BRCA2 germline panels for validation by cancer centers and clinical testing companies in the US and China. The company emphasizes faster data delivery, lower costs, and broader access to localized diagnostics through its proprietary technology.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies for cancer patients. It specializes in oncolytic immunotherapy, focusing on bladder cancer treatments.

Enable Injections designs and manufactures wearable devices that deliver injectable drugs directly into the subcutaneous tissue. The system accepts standard vials, syringes, or cartridges, automatically reconstitutes lyophilized solutions, warms the drug, and injects high‑viscosity or high‑volume payloads up to 20 ml. Users place the device on the skin, press a central button, and monitor delivery progress through a viewing window before disposing of the single‑use injector. The company also offers transfer systems for partial or multi‑vial filling and a Bluetooth‑enabled version that can connect to smartphones. Founded in 2010, the company is headquartered in Cincinnati, Ohio, and targets a growing market for self‑administration of biologics and other therapeutics.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

TriSalus Life Sciences specializes in developing precision infusion systems for interventional radiology, focusing on targeted drug delivery to treat liver cancer and other solid tumors. The company's flagship products include the Surefire precision infusion systems designed for lobar, segmental, and super-selective infusions, as well as guiding catheters. TriSalus also develops Pressure Enabled Drug Delivery (PEDD) infusion systems and investigational agents like nelitolimod to enhance immune response in cancer treatment.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Enable Injections designs and manufactures wearable devices that deliver injectable drugs directly into the subcutaneous tissue. The system accepts standard vials, syringes, or cartridges, automatically reconstitutes lyophilized solutions, warms the drug, and injects high‑viscosity or high‑volume payloads up to 20 ml. Users place the device on the skin, press a central button, and monitor delivery progress through a viewing window before disposing of the single‑use injector. The company also offers transfer systems for partial or multi‑vial filling and a Bluetooth‑enabled version that can connect to smartphones. Founded in 2010, the company is headquartered in Cincinnati, Ohio, and targets a growing market for self‑administration of biologics and other therapeutics.

Pillar Biosciences develops next-generation sequencing based assays and software for NGS laboratories. It offers SLIMamp, a Stem-Loop Inhibition-Mediated amplification technology that enables specific priming of overlapping target segments, and PiVAT, an integrated bioinformatics analysis pipeline that produces an enhanced PBAM file for improved local realignment and read assembly. Founded in 2014, the company is headquartered in Natick, Massachusetts, with a presence in Shanghai, China. Its platform focuses on targeted sequencing to support treatment decisions in oncology, delivering high sensitivity and specificity for clinical samples. Pillar has released targeted panels such as Lung and Colon Cancer Somatic Mutation Panel and BRCA1/BRCA2 germline panels for validation by cancer centers and clinical testing companies in the US and China. The company emphasizes faster data delivery, lower costs, and broader access to localized diagnostics through its proprietary technology.